Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Seeks HCC Indication for Lenvima in Japan
June 26, 2017
- Kyowa Kirin, LEO Pharma Tie Up for Gel Version of Dovobet Too
June 23, 2017
- Bioverativ Japan Files 4,000 IU Version for Hemophilia B Treatment Alprolix
June 23, 2017
- Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?
June 22, 2017
- EA Pharma to Discontinue Lentinan Sales amid Dwindling Demand
June 22, 2017
- Atsuo Takahashi Becomes Toa Eiyo President
June 22, 2017
- Takeda’s New Solid Dosage Form Production Facilities Completed in Germany
June 21, 2017
- Zeria to Terminate Development of Novel PPI
June 21, 2017
- Seikagaku Begins US PII Study of SI-613 for Knee Osteoarthritis
June 21, 2017
- Mitsubishi Tanabe Wins Fingolimod Patent Infringement Lawsuit in US
June 21, 2017
- Amgen Astellas Biopharma Gearing Up for 2020 Takeoff as Stand-Alone Subsidiary
June 20, 2017
- Takecab Most Heavily Promoted Drug for Hospital Doctors in April: Anterio
June 19, 2017
- Biogen Japan Upbeat on Tecfidera, Near-Approval Nusinersen, Sakigake Boost for Aducanumab
June 19, 2017
- Kaken, Numab Strike Deal for Multi-Specific Antibody in Inflammatory Disease
June 14, 2017
- Ethical Drug Sales Sag 10.4% in April: Crecon
June 14, 2017
- Takeda Consumer Healthcare Looks to Stable, Sustainable Growth: President
June 13, 2017
- PeptiDream Licenses Peptide Discovery Platform to Shionogi
June 13, 2017
- Mochida, Ayumi Hook Up on Sales of Enbrel, Humira Biosimilars
June 13, 2017
- Kissei Gets Japan Rights to Avacopan for Rare Kidney Diseases
June 12, 2017
- Lurasidone Beats Primary Endpoint in Bipolar I Depression: Sumitomo Dainippon
June 12, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…